A股異動 | 揚農化工(600486.SH)盤中漲停 績後獲多家券商唱好
格隆匯10月28日丨揚農化工(600486.SH)盤中曾大幅拉昇漲停,現報95.4元,暫成交6.3億元,總市值295.6億元。揚農化工26日公告,前三季實現營業收入79.56億元,同比增長12.67%;淨利小幅下降4.34%至10.23億元。扣非後歸母淨利潤9.53億元,同比增加20.11%。興業證券表示,公司匯兑損益等影響單季度業績,扣非後業績實現較快增長,項目豐富成長或提速。方正證券指出,公司除草劑銷量大幅增長,看好長期成長。華西證券認為,公司業績穩定增長,優嘉三期及瀋陽科創為未來增收亮點。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.